#personalizedtreatment
HSCT-64, a 64-gene #Transcriptomic #RiskModel enables #Diagnosis-time identification of pediatric #AML patients most likely to benefit from #Transplantation, providing a practical approach for #PersonalizedTreatment.

#OpenAccess: doi.org/10.1016/j.ge...
January 15, 2026 at 12:45 AM
This review summarizes LPA signaling, from #Biosynthesis and receptor pathways to #TherapeuticTargets, and presents an AI model that simulates network dynamics for predictive and #PersonalizedTreatment. #medsky @ou.edu

#STTT #OpenAccess: doi.org/10.1038/s413...
November 20, 2025 at 4:45 PM
These hernias develop anywhere along the midline of your abdomen. Our surgical approach considers hernia size, location, and your overall health for customized treatment.

#CustomizedCare #SahajHospitalIndore #AbdominalSurgery #PersonalizedTreatment
October 11, 2025 at 6:47 AM
JMIR Formative Res: A Series of Personalized Melatonin Supplement Interventions for Poor Sleep: #feasibility Randomized Crossover Trial for Personalized N-of-1 Treatment #Melatonin #SleepHealth #PersonalizedTreatment #Nof1Trials #SleepQuality
A Series of Personalized Melatonin Supplement Interventions for Poor Sleep: #feasibility Randomized Crossover Trial for Personalized N-of-1 Treatment
Background: Poor sleep (defined by short sleep duration or poor quality) is a common condition with potential serious health consequences. Exogeneous melatonin supplements have been found to effectively improve poor sleep but have also been shown to have heterogeneity of treatment effects (HTEs) between individuals. Personalized N-of-1 trials, in which each participant is the unit of analysis, are ideal for identifying whether a treatment with high HTE is beneficial for each individual patient. Objective: This study aimed to identify the #feasibility, acceptability, and effectiveness of a series of personalized N-of-1 trials of melatonin for poor sleep. Methods: This study consisted of 60 digital, personalized N-of-1 crossover trials comparing the effects of 3.0mg and 0.5mg of melatonin versus placebo for poor sleep with randomization to 1 of 2 orders. The trial was comprised of a 2-week baseline period and a 12-week intervention period. The primary outcomes were #usability of the personalized trial system (measured using the System #usability Scale [SUS]) and participant satisfaction with the trial. Effectiveness outcomes included sleep duration (measured using a Fitbit activity tracker) and sleep quality (measured using the consensus sleep diary [CSD]). Results: Participants rated the #usability of the personalized trial as acceptable (average SUS score=76.3 [standard deviation (SD)=17.1]), and 96% (55/57) of those who completed satisfaction surveys stated that they would recommend the trial to others. Importantly, indices of HTE were low for 3.0mg and 0.5mg doses of melatonin, indicating that the effect of these treatments on sleep duration and sleep quality did not substantially vary between participants and that averaged treatment responses are appropriate. Averaged participant sleep duration did not significantly differ between the 3.0mg (P=0.7) and 0.5mg (P=0.9) melatonin intervention periods and the baseline period. Additionally, regression models did not show differences between different levels of melatonin and placebo periods for sleep duration or quality. Conclusions: Participant ratings of the #usability of and satisfaction with this series of personalized N-of-1 trials of melatonin for sleep suggest these trials are both feasible and acceptable. However, our results show that melatonin supplements did not significantly improve sleep duration or sleep quality. Further, the treatment effects’ lack of heterogeneity between participants suggests that future use of N-of-1 trials of melatonin for poor sleep is not needed.
dlvr.it
September 26, 2025 at 6:33 PM
Exciting news! A new paper has been accepted in Behavior Therapy:

Congrats to @clarissaong.bsky.social, @claireecusack.bsky.social, and @cherilev.bsky.social on this important contribution!

#PersonalizedTreatment #NetworkTheory #EatingDisordersTreatment
September 22, 2025 at 11:07 PM
#Transcriptomics identified four molecular subtypes of HR+/HER2+ #BreastCancer (BC), each exhibiting unique biological signatures, pathway activation patterns, & differential treatment responses, facilitating #PersonalizedTreatment.

#STTT #OpenAccess: doi.org/10.1038/s413...
September 19, 2025 at 5:30 AM
This study demonstrates significant differences in #intestinalflora structures and metabolite abundance between #chemotherapy-sensitive and #drugresistant patients, thereby offering potential #biomarkers for the formulation of #personalizedtreatment strategies.

bio-integration.org/intestinal-m...
Effects of the Intestinal Microbiome and Metabolites on Neoadjuvant Chemotherapy Efficacy in Breast Cancer
Announcing a new article publication for BIO Integration journal. Imbalances in the intestinal microbiome are closely associated with the occurrence and development of cancer, and can affect tumorigen...
bio-integration.org
July 14, 2025 at 1:56 PM
We should move away from traditional, often slow and one-size-fits-all methods towards more personalized, innovative, and adaptable strategies.

#Cancer #Kanser #CancerCare #CancerTreatment #PersonalizedTreatment #MedSky #PrecisionOncology
May 23, 2025 at 11:31 AM
To fully realize the potential of precision medicine in cancer care, a fundamental shift is needed in how we approach research, treatment, and regulation.

Reference: www.nature.com/articles/s41...

#Cancer #Kanser #CancerCare #CancerTreatment #PersonalizedTreatment #MedSky #PrecisionOncology
May 23, 2025 at 11:31 AM
The current status and future directions of artificial intelligence in the prediction, diagnosis, and treatment of liver diseases - Apr 13, 2025
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#AI #earlydetection #hepatology #personalizedtreatment #medsky #openaccess
April 18, 2025 at 9:37 PM
Dr. Eric Singhi now live, presenting Understanding Resistance to Targeted Therapy in Non-Small Cell Lung Cancer.

#TargetedTherapies #LungCancer #MolecularTesting #PersonalizedTreatment #NSCLC
March 15, 2025 at 5:08 PM
Differentiating idiopathic Parkinson’s disease from multiple system atrophy-P using brain MRI-based radiomics: a multicenter study - Feb 26, 2025
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#diagnosis #diagnostics #neurology #personalizedtreatment #openaccess
March 13, 2025 at 5:51 PM
Tryptophan metabolites profile predict remission with dietary therapy in pediatric Crohn’s disease - Feb 25, 2025
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#biomarker #gastroenterology #personalizedtreatment #openaccess
March 13, 2025 at 5:48 PM
Why does addiction affect some people but not others? Brenna studies how experiences and genetics underlie addiction to help develop personalized treatments.
#addiction #addictiontreatments #neurosky #academicsky #personalizedtreatment #investinscience
March 11, 2025 at 3:03 PM
Key point: Early onset genetic DEEs offer a valuable model to explore the neurobiological process underlying the epilepsy–autism phenotype.
doi.org/10.1111/epi....

#epilepsy #ILAE #autismspectrumdisorder #DEE #DEEassociatedgenes #personalizedtreatment
March 4, 2025 at 3:34 PM
Researchers discover a significant correlation between delayed gastric emptying time and the body-first subtype of Parkinson's disease, paving the way for more personalized treatment plans #Parkinsons #GastricEmptying #PersonalizedTreatment https://curedigest.com/science-news/parkinsons/gastric-e...
January 21, 2025 at 9:35 AM